Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Two translational studies at the Vanderbilt Eye Institute are targeting photoreceptors and retinal ganglion cells (RGCs) to restore vision through regeneration of the retina. The research is funded by the NEI Audacious Goals Initiative.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
Research from the University of Utah explains why people with genetic variants may develop age-related macular degeneration (AMD) and identifies a potential therapeutic pathway for slowing disease progression.
As regenerative therapies for blinding diseases move closer to clinical trials, the NEI's functional imaging consortium is pioneering noninvasive technologies to monitor the function of the retina’s neurons and their connections to the brain.
Researchers at the University of Wisconsin have developed a micro-molded scaffolding photoreceptor “patch” designed to be implanted under a damaged or diseased retina.
LambdaVision, the Farmington, Connecticut-based biotech firm that developed the artificial retina, is exploring optimizing production of an artificial retina in space, in a series of missions to the International Space Station.
Scientists at the University of Pennsylvania School of Veterinary Medicine report findings of a gene therapy to treat a severe form of Leber congenital amaurosis, caused by mutations in the NPHP5 gene.
NEI-funded research at the University of Rochester has led to the development of a 3D lab model that mimics the part of the human retina affected in age-related macular degeneration.